Anika Therapeutics Receives Health Canada Approval for Cingal Device

Anika Therapeutics has received Health Canada approval for its Cingal medical device to treat pain associated with osteoarthritis of the knee.

Cingal is a combination viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, an FDA-approved steroid to treat inflammation.

Osteoarthritis is the most common joint disease in the world, affecting more than 5 percent of the global population, the Bedford, Mass.-based company says.

Cingal is Anika’s third-generation viscosupplementation product. — Michael Cipriano